These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
301 related articles for article (PubMed ID: 27374030)
21. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. Chen X; Xie H; Wood BL; Walter RB; Pagel JM; Becker PS; Sandhu VK; Abkowitz JL; Appelbaum FR; Estey EH J Clin Oncol; 2015 Apr; 33(11):1258-64. PubMed ID: 25732155 [TBL] [Abstract][Full Text] [Related]
22. Genomic, immunophenotypic, and NPM1/FLT3 mutational studies on 17 patients with normal karyotype acute myeloid leukemia (AML) followed by aberrant karyotype AML at relapse. Wang ES; Sait SN; Gold D; Mashtare T; Starostik P; Ford LA; Wetzler M; Nowak NJ; Deeb G Cancer Genet Cytogenet; 2010 Oct; 202(2):101-7. PubMed ID: 20875872 [TBL] [Abstract][Full Text] [Related]
23. Stratification of de novo adult acute myelogenous leukemia with adverse-risk karyotype: can we overcome the worse prognosis of adverse-risk group acute myelogenous leukemia with hematopoietic stem cell transplantation? Yoon JH; Kim HJ; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW Biol Blood Marrow Transplant; 2014 Jan; 20(1):80-8. PubMed ID: 24149098 [TBL] [Abstract][Full Text] [Related]
24. AML evolution from preleukemia to leukemia and relapse. Shlush LI; Mitchell A Best Pract Res Clin Haematol; 2015; 28(2-3):81-9. PubMed ID: 26590763 [TBL] [Abstract][Full Text] [Related]
25. Genomic complexity and dynamics of clonal evolution in childhood acute myeloid leukemia studied with whole-exome sequencing. Masetti R; Castelli I; Astolfi A; Bertuccio SN; Indio V; Togni M; Belotti T; Serravalle S; Tarantino G; Zecca M; Pigazzi M; Basso G; Pession A; Locatelli F Oncotarget; 2016 Aug; 7(35):56746-56757. PubMed ID: 27462774 [TBL] [Abstract][Full Text] [Related]
26. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience. Plesa C; Chelghoum Y; Plesa A; Elhamri M; Tigaud I; Michallet M; Dumontet C; Thomas X Cancer; 2008 Feb; 112(3):572-80. PubMed ID: 18085638 [TBL] [Abstract][Full Text] [Related]
27. Acute myeloid leukaemia: expression of MYC protein and its association with cytogenetic risk profile and overall survival. Mughal MK; Akhter A; Street L; Pournazari P; Shabani-Rad MT; Mansoor A Hematol Oncol; 2017 Sep; 35(3):350-356. PubMed ID: 26856970 [TBL] [Abstract][Full Text] [Related]
28. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression. Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965 [TBL] [Abstract][Full Text] [Related]
37. Failure matters: unsuccessful cytogenetics and unperformed cytogenetics are associated with a poor prognosis in a population-based series of acute myeloid leukaemia. Lazarevic V; Hörstedt AS; Johansson B; Antunovic P; Billström R; Derolf Å; Lehmann S; Möllgård L; Peterson S; Stockelberg D; Uggla B; Vennström L; Wahlin A; Höglund M; Juliusson G Eur J Haematol; 2015 May; 94(5):419-23. PubMed ID: 25200361 [TBL] [Abstract][Full Text] [Related]
38. Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals. Ommen HB; Nyvold CG; Braendstrup K; Andersen BL; Ommen IB; Hasle H; Hokland P; Ostergaard M Br J Haematol; 2008 Jun; 141(6):782-91. PubMed ID: 18410450 [TBL] [Abstract][Full Text] [Related]
39. Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia. Medeiros BC; Othus M; Fang M; Appelbaum FR; Erba HP Haematologica; 2015 Mar; 100(3):331-5. PubMed ID: 25527568 [TBL] [Abstract][Full Text] [Related]
40. Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia? Yilmaz M; Wang F; Loghavi S; Bueso-Ramos C; Gumbs C; Little L; Song X; Zhang J; Kadia T; Borthakur G; Jabbour E; Pemmaraju N; Short N; Garcia-Manero G; Estrov Z; Kantarjian H; Futreal A; Takahashi K; Ravandi F Blood Cancer J; 2019 Jan; 9(2):7. PubMed ID: 30651532 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]